WeVote
Log In

Bill

Bill

SCR 22

PHARMACEUTICALS: Requests a legislative auditor report on opioid settlement fund expenditures.

2026 Regular Session Introduced by Regina Barrow and 7 co-sponsors

Louisiana legislature requests auditor investigate how state spent opioid settlement funds to ensure accountability and identify spending gaps or inefficiencies.

Signed by the Speaker of the House.
0
WeVote Research Nonpartisan
Bill Summary · SCR 22

Legislative bill overview

SCR 22 requests that Louisiana's legislative auditor conduct a comprehensive report examining how the state has spent funds received from opioid settlement agreements. The bill seeks transparency and accountability regarding these settlement monies, which typically come from litigation against pharmaceutical companies over their role in the opioid crisis.

Why is this important

Opioid settlements have provided billions in funding to states nationwide for addiction treatment, prevention, and recovery programs. A legislative audit ensures taxpayer money is being used effectively and as intended, and can identify gaps or inefficiencies in how Louisiana allocates these resources to address its opioid crisis.

Potential points of contention

  • Scope and timeline: The bill doesn't specify which settlement funds to audit, what time period to cover, or whether the audit includes recommended spending plans that weren't followed
  • Resource allocation: An audit may reveal that settlement funds were diverted to non-opioid-related purposes or insufficiently targeted to affected communities, raising questions about state priorities
  • Implementation readiness: The report could expose inadequate infrastructure or capacity to deploy funds effectively, potentially embarrassing state agencies or requiring additional appropriations

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.